The impact of rotigotine on cardiovascular autonomic function in early parkinson's disease

European Neurology

Volumn 68, Issue 3, 2012, Pages 187-192

  Rocchi, Camilla ^a   Pierantozzi, Mariangela ^a,b   Pisani, Valerio ^a   Marfia, Girolama Alessandra ^a   Di Giorgio, Alessandra ^a   Stanzione, Paolo ^a,b   Bernardi, Giorgio ^a,b   Stefani, Alessandro ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Autonomic function tests; Dopamine agonists; Orthostatic hypotension; Parkinson's disease; Rotigotine

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ROTIGOTINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSAUTONOMIA; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UNIFIED PARKINSON DISEASE RATING SCALE;

ADOLESCENT; ADULT; AGED; ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HAND STRENGTH; HEART RATE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RESPIRATION; STATISTICS, NONPARAMETRIC; TETRAHYDRONAPHTHALENES; THIOPHENES; VALSALVA MANEUVER; YOUNG ADULT;

EID: 84865586582     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000339000     Document Type: Article

References (38)

1. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH: The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007; 22: 1901-1911.
2. Magerkurth C, Schnitzer R, Braune S: Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin Auton Res 2005; 15: 76-82.
3. Gross M, Bannister R, Godwin-Austen R: Orthostatic hypotension in Parkinson's disease. Lancet 1972; 1: 174-176.
4. Goldstein DS: Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006; 16: 46-54.
5. Schoenberger JA: Drug-induced orthostatic hypotension. Drug Saf 1991; 6: 402-407.
6. Johns DW, Ayers CR, Carey RM: The dopamine agonist bromocriptine induces hypotension by venous and arteriolar dilation. J Cardiovasc Pharmacol 1984; 6: 582-587.
7. Tayebati SK, Lokhandwala MF, Amenta F: Dopamine and vascular dynamics control: present status and future perspectives. Curr Neurovasc Res 2011; 8: 246-257.
8. Valldeoriola F, Cobaleda S, Lahuerta J: A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: the ROPI-PARK study. Clin Neurol Neurosurg 2009; 111: 742-747.
9. Etminan M, Gill S, Samii A: Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003; 26: 439-444.
10. Perez-Lloret S, Bondon-Guitton E, Rascol O, Montastruc JL, French Association of Regional Pharmacovigilance Centers: Adverse drug reactions to dopamine agonists: a comparative study in the French Pharmacovigilance Database. Mov Disord 2010; 25: 1876-1880.
11. Wood LD: Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease. Drugs Aging 2010; 27: 295-310.
12. Jenner P: A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005; 65:S3-S5.
13. Fahn S, Elton RL, Members of the UPDRS Development Committee: Unified Parkinson's Disease Rating Scale; in Fahn S, Marsden CD, Calne DB, Goldstein M (eds): Recent Developments in Parkinson's Disease, vol 2. Florham Park, NJ, Macmillan Health Care Information, 1987, pp 153-163, 293-304.
14. Schillaci O, Chiaravalloti A, Pierantozzi M, Di Pietro B, Koch G, Bruni C, Stanzione P, Stefani A: Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT. Int J Mol Med 2011; 28: 881-886.
15. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH: Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007; 22: 2398-2404.
16. Mathias CJ, Bannister R: Investigation of autonomic disorders; in Mathias CJ, Bannister R (eds): Autonomic Failure. A Textbook of Clinical Disorders of the Autonomic Nervous System, ed 4. Oxford, Oxford University Press, 1999, pp 169-195.
17. Rocchi C, Greco V, Urbani A, Di Giorgio A, Priori M, Massa R, Bernardi G, Marfia GA: Subclinical autonomic dysfunction in spinobulbar muscular atrophy (Kennedy's disease). Muscle Nerve 2011; 44: 737-740.
18. Benarroch EE: Central neurotransmitters and neuromodulators in cardiovascular regulation; in Mathias CJ, Bannister R (eds): Autonomic Failure. A Textbook of Clinical Disorders of the Autonomic Nervous System, ed 4. Oxford, Oxford University Press, 1999, pp 37-44.
19. Shindo K, Iida H, Watanabe H, Ohta E, Nagasaka T, Shiozawa Z: Sympathetic sudomotor and vasoconstrictive neural function in patients with Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 548-552.
20. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K: Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre-and postganglionic neurons. Acta Neuropathol 2007; 113: 421-429.
21. Turkka JT, Juujärvi KK, Lapinlampi TO, Myllylä VV: Serum noradrenaline response to standing up in patients with Parkinson's disease. Eur Neurol 1986; 25: 355-361.
22. Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM: Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2011; 17: 724-729.
23. Barbic F, Perego F, Canesi M, Gianni M, Biagiotti S, Costantino G, Pezzoli G, Porta A, Malliani A, Furlan R: Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension. Hypertension 2007; 49: 120-126.
24. Stowe R, Ives N, Clarke CE, Deane K, van Hilten, Wheatley K, Gray R, Handley K, Furmston A: Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev 2010; 7:CD007166.
25. Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J, Goetz C, Ranhosky A, Korts D, Elvin A: Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18: 338-347.
26. Jost WH, Bellon AK, Kaiser T, Schrank B: The impact of ropinirole on blood pressure and noradrenaline concentration after active orthostasis in Parkinsonian patients. Parkinsonism Relat Disord 1998; 4: 61-63.
27. Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG: Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000; 57: 1461-1463.
28. Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM, Beck B, Paume D, Doyle C: The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism Relat Disord 2001; 7: 115-120.
29. Nashatizadeh MM, Lyons KE, Pahwa R: A review of ropinirole prolonged release in Parkinson's disease. Clin Interv Aging 2009; 4: 179-186.
30. Lloret SP, Rey MV, Ratti L, Rascol O: Pramipexole for the treatment of early Parkinson's disease. Expert Rev Neurother 2011; 11: 925-935.
31. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators: Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a doubleblind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-520.
32. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, Recover Study Group: Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90-99.
33. Zeng C, Wang D, Yang Z, Wang Z, Asico LD, Wilcox CS, Eisner GM, Welch WJ, Felder RA, Jose PA: Dopamine D1 receptor augmentation of D3 receptor action in rat aortic or mesenteric vascular smooth muscles. Hypertension 2004; 43: 673-679.
34. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H: The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 73-86.
35. Van Zwieten PA, Blauw GJ, van Brummelen P: Serotonergic receptors and drugs in hypertension. Pharmacol Toxicol 1992; 70:S17-S22.
36. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. Pharmacol Exp Ther 2002; 303: 791-804.
37. Fasano A, Guidubaldi A, De Nigris F, Bentivoglio AR: Safety and efficacy of rotigotine in individuals with Parkinson's disease aged 75 and older. J Am Geriatr Soc 2011; 59: 2386-2387.
38. Jenner P, McCreary AC, Scheller DK: Continuous drug delivery in early-and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm 2011; 118: 1691-1702.